A study that evaluates the effectiveness of oral medicinal cannabis for people with advanced cancer experiencing a range of symptoms.
Oral Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer: a double-blind, placebo controlled, randomised clinical trials of efficacy and safety of cannabidiol (CBD)
Mater Misericordiae Limited
144 participants
Feb 13, 2019
Interventional
Conditions
Summary
The purpose of this study is to assess whether cannabidoil (CBD) can be used to reduce total symptoms in patients with advanced cancer in palliative care. Who is it for? You may be eligible for this study if you are over 25 years of age and have been diagnosed with advanced cancer. Study details Participants will be randomly assigned to one of two treatment groups; either CBD or a placebo medication. Participants will be asked to take increasing doses of the study medication for 14 days, with the dose increasing until participants are satisfied with the symptom improvement and are experiencing no unacceptable side effects. After these 14 days, participants will be asked to take a steady dose of the medication for another set of 14 days. During the 28 days of the study you will be required to have a routine blood and urine test taken to determine if you are eligible. A further blood test will be taken at day 14 post trial analysis. It is hoped that this research will show a positive effect of CBD on symptoms for patients suffering with advanced cancer and thus provide an option in helping manage symptoms.
Eligibility
Inclusion Criteria13
- Patients with advanced histologically proven cancer (metastatic or locally advanced) known to the palliative care team:
- have an ESAS TSDS greater than 10
- at least one individual ESAS score greater than 3
- AKPS score >30
- aged >25yrs and above. English speaking (or have interpreter available)
- have a negative pregnancy urine test at eligibility (only if of reproductive potential) and agree to avoid pregnancy during the study and 12 weeks following the last dose of the study drug. Males must agree to avoid fathering a child and to not donate sperm during the study and for at least 12 weeks following the last dose of the study drug
- have a negative THC urine test
- able to tolerate oral medication and comply with trial requirments
- agree to use no other cannabis based products for the duration of the trial
- comply with trial requirements: agree to attend scheduled clinical appointments, adhere to dose titration schedule as directed
- understand it is illegal to take cannabinoid products outside of Australia
- understand that it is illegal to drive whilst taking cannabis products
- able to provide fully informed consent
Exclusion Criteria11
- a history of hypersensitivity to any cannabinoid product
- unstable untreated cardiovascular disease (hypertension, ischemic heart disease, congestive cardiac failure)
- severe hepatic impairment (total bilirubin >1.5 times the upper limit of the institution's normal range. Asparate aminotransferase (AST), and alanne aminotransferase (ALT) >3.0 time the upper limit of the institution's normal range; subjects with liver metastasis may have an AST and ALT of >5.0 times the upper limit of normal
- severe renal impairment (eGFR <20mls/min/1.73m2)
- history of psychiatric disorders (severe depression or anxiety, personality disorder, psychosis, schizophrenia, first degree relative with schizophrenia and/or suicidal ideation)
- cognitive impairment (SLUMS - St Louis University Mental Status) examination <20/30
- known substance use disorder (ASSIST - Alcohol, Smoking and Substance Involvement Screening Test) examination score >27+
- history that drug diversion may be a risk for them or their family/carers
- females who are pregnant or lactating
- concurrent or participation of a new clinical entity with the last 28 dyas
- treatment with a new specific anticancer agent (chemotherapy, targeted or hormonal therapy) or radiation within the last 7 days
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients with advanced cancer will participate in a double-blind, placebo controlled, and randomisation clinical trial. Each participant will follow a dose titration schedule for 14 days and a follow on stable dose for a further 14 days. Participants will be allocated into a treatment arm according to a block randomisation schedule held by a central registry. There will be one active arm (CBD) and an inert oral oily liquid (placebo). Concentration of medication: CBD (Cannabidiol) 100mg/ml oral oily liquid (dose range 50mg – 600mg/day Dosing schedule: Dose titration (days 0 – 14) will be confirmed by the treating doctor with doses starting at: Arm 1 Days 0 & 1 – 1 dose/day = total daily dose 50mg (0.5ml) Day 2 & 3 – 1 dose/day = total daily dose 100mg (1ml) Day 4 & 5 – 2 dose/day = total daily dose 200mg (2ml) Day 6 & 7 – 3 doses/day = total daily dose 300mg (3ml) Day 8 & 9 – 3 doses/day = total daily dose 400mg (4ml) Day 10 & 11 – 3 doses/day = total daily dose 500mg (5ml) Day 12 & 13 – 3 doses/day = total daily dose 600mg (6ml) Day 14 – 28 – Continue on final dose reached Each participant will be advised to increase their dose according to the dosing schedule until they are satisfied with symptom improvement and no unacceptable side effects (according to the CTCAE graded >4 (confusion, somnolence, personality change, paranoia, anxiety, mood change, psychosis, hypertension, tachycardia, sweating, nausea, vomiting, abdominal pain)). The patient then will be given the option of remaining on the cannabinoid preparation for continuing assessment of efficacy and adverse events for a further 14 days totaling 28 days on the study drug. Patients will have the choice of lowering their dose according to symptom improvement. Dose titration downwards will be in consultation with the doctor. Participants will be required to return empty/unused bottles each clinic visit to receive a further supply.
Locations(6)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001220257